Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01706523 · ClinicalTrials.gov registry record · Phase 3
Open Label Extension Study of STX209 (Arbaclofen) in Autism Spectrum Disorders
A Phase 3 study, sponsored by Seaside Therapeutics.
- Terminated
- Registry status
- Phase 3
- Development phase
- 165
- Enrollment target
NCT01706523: Clinical Trial Phase 3 study, sponsored by Seaside Therapeutics.
NCT01706523 is a Phase 3 study that was terminated before completion, run by Seaside Therapeutics. The registered enrollment target is 165 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (79% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01706523, a Phase 3 study, was terminated before completion, sponsored by Seaside Therapeutics.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 165 participants
- Enrollment target
Study Summary
This is an open-label extension protocol that will provide necessary data on the safety, tolerability, pharmacokinetics and efficacy of STX209 among subjects with ASD.
Primary Outcome
Spontaneously-reported adverse events, physical examination, and clinical laboratory assessments
Interventions
- DRUG STX209 (arbaclofen)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 165 participants |
| Start Date | 2011-11 |
| Est. Completion | 2013-07 |
| Phase | Phase 3 |
Why NCT01706523 stopped before completion
NCT01706523 is an interventional study that assigns participants to a tested intervention. The registered 165 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (79% lower).
The record links to 0 conditions, and to 1 intervention - of which STX209 (arbaclofen) is the first listed.
NCT01706523 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01706523 about?
NCT01706523 is a clinical study titled "Open Label Extension Study of STX209 (Arbaclofen) in Autism Spectrum Disorders". This is an open-label extension protocol that will provide necessary data on the safety, tolerability, pharmacokinetics and efficacy of STX209 among subjects with ASD.
What is the current status of trial NCT01706523?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 165 participants. The study started on 2011-11. Estimated completion is 2013-07.
What interventions are being tested in trial NCT01706523?
The interventions under investigation include: STX209 (arbaclofen) (DRUG).
Who is sponsoring clinical trial NCT01706523?
This trial is sponsored by Seaside Therapeutics, which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01706523's enrollment target sits among peer trials
165 1465th of 2000 higher than 531 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02387255 · 165 participants
Magnetic Resonance Elastography in Patients With Abdominal Aortic Aneurysms
- NCT03351348 · 165 participants · Phase 3
Bupivacaine vs Placebo for Unilateral Mastectomy Surgical Site Post-operative Pain Control
- NCT03830320 · 165 participants · Phase 1
Positron Emission Tomography (PET) Imaging of Thrombosis
- NCT04289571 · 165 participants · Phase 1
Virtual Reality Mobility Assessment of Functional Vision in Retinal Disease
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia